Polypharmacy- Purpose, Benefits and Limitations
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
With what has become increasingly common among nearly all medical specialties, the number of patients who have various comorbid diseases both psychiatrically and mentally challenges the field of psychiatry. As a result, it is not uncommon for physicians to be imposed with treatment decisions regarding polypharmacy, the use of multiple medications to treat different diseases, or even the same illness several times. In recent years, the concept of polypharmacy has been known to have a negative undertone, implying that its use is inappropriate or causes more harm than the potential benefit. Although the use of any medication should involve risk versus benefit discussion, when used with good clinical judgment and pharmacologically sound knowledge, this practice can be potentially life-altering for patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Risperidone in the treatment of schizophrenia
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.6.825 · Cited by 1,193
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
DEFINITION AND EPIDEMIOLOGY OF TREATMENT-RESISTANT DEPRESSION
Fava, M., & Davidson, K. G. (1996) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(05)70283-5 · Cited by 797
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Frank, A. F. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810150028006 · Cited by 552
Nierenberg, A. A., Husain, M. M., Trivedi, M. H., Fava, M., Warden, D., Wisniewski, S. R., Miyahara, S., & Rush, A. J. (2010) · Psychological Medicine · doi:10.1017/s0033291709006011 · Cited by 458
Reducing the global burden of depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Kieling, C., McGorry, P., Horton, R., Sargent, J., & Patel, V. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32408-5 · Cited by 418
Dose Response and Dose Equivalence of Antipsychotics
Davis, J. M., & Chen, N. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117422.05703.ae · Cited by 358
Research works printed but not linked: 2
- Stahl S.M.; Stahl’s essential psychopharmacology: Neuroscientific basis and practical application 2013
- Stahl Morrissette D.; Should high dose or very long-term antipsychotic monotherapy be considered before antipsychotic polypharmacy? Polypharmacy in Psychiatry Practice 2013,107-125
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationWrześniewska-Wal, I., Pinkas, J., Ostrowski, J., & Jankowski, M. (2023) · Healthcare · doi:10.3390/healthcare11172444 · Cited by 15
“, taking at least five drugs per day (including preparations used in unconventional medicine) [34,35].”
BackgroundDegraff, Z., Souza, G. D. S., dos Santos, N. A., Shoshina, I. I., Felisberti, F. M., Fernandes, T. P., & Sigurdsson, G. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.05.074 · Cited by 6
Biomarkers and Emerging Drug Targets in Neuropsychiatry (Part I)
Marazziti, D. (2022) · Current Medicinal Chemistry · doi:10.2174/092986732935220907150412 · Cited by 2
Is Polypharmacy pandemic coming, or is it already here?
Panov, V. (2024) · Journal of Medical and Dental Practice · doi:10.18044/medinform.2024112.1939
Metadata
- Authors
- Grover, D., Tom, M., Maguire, G., & Stahl, S.
- Affiliations
- University of California, Riverside (US)
- Corresponding author
- Grover, Douglas
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2022-10
- Volume
- 29
- Issue
- 35
- Pages
- 5606-5614
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W4205166434
- Cited by
- 7
- References
- 40
- Citations by year
- 2026: 2 · 2024: 1 · 2023: 3 · 2022: 1
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Health Sciences › Health Professions › Pharmacy › Pharmacy and Medical Practices
- Keywords
- polypharmacy, multiple drugs, comorbidities, mental illness, risk-benefit assessment, medication management
- MeSH terms
- Humans, Polypharmacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polypharmacy- Purpose, Benefits and Limitations. https://app.cochat.ai/papers/10.2174/0929867329666220107153813
- The paper
- Grover, D., Tom, M., Maguire, G., & Stahl, S. (2022). Polypharmacy- Purpose, Benefits and Limitations. Current Medicinal Chemistry. https://doi.org/10.2174/0929867329666220107153813
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.